• レポートコード:QYR2104Z3017 • 出版社/出版日:QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態:英文、PDF、127ページ • 納品方法:Eメール(納期:3日) • 産業分類:医療 |
Single User | ¥553,800 (USD3,900) | ▷ お問い合わせ |
Multi User/Five User | ¥830,700 (USD5,850) | ▷ お問い合わせ |
Enterprise License(同一法人内共有可) | ¥1,107,600 (USD7,800) | ▷ お問い合わせ |
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
QYResearch社発行の本調査資料では、特発性頭蓋内圧亢進症治療のグローバル市場(2016年~2027年)について調べ、市場動向、主要企業の市場シェア、種類別市場規模(アセタゾラミド、メタゾラミド、フロセミド、トピラマート、その他)、用途別市場規模(病院、クリニック、外来手術センター)、主要地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、関連企業情報などを掲載しています。 ・市場概要 ・特発性頭蓋内圧亢進症治療の市場動向 ・企業の競争状況、市場シェア ・特発性頭蓋内圧亢進症治療の種類別市場規模(アセタゾラミド、メタゾラミド、フロセミド、トピラマート、その他) ・特発性頭蓋内圧亢進症治療の用途別市場規模(病院、クリニック、外来手術センター) ・特発性頭蓋内圧亢進症治療の北米市場規模2016-2027(アメリカ、カナダ) ・特発性頭蓋内圧亢進症治療のヨーロッパ市場規模2016-2027(ドイツ、フランス、イギリス等) ・特発性頭蓋内圧亢進症治療のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等) ・特発性頭蓋内圧亢進症治療の中南米市場規模2016-2027(メキシコ、ブラジル) ・特発性頭蓋内圧亢進症治療の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等) ・主要企業情報(Avkare, Inc、FDC、Heritage Pharmaceuticals Inc、Ingenus Pharmaceuticals、Janssen - Cilag Pharmaceuticals SA、Lannett Company,、Medtronic、MercuryPharma、Nostrum Laboratories Inc、Novast Holdings Ltd.、Sanofi、SGPharma Pvt. Ltd.、Sophysa、Taro Pharmaceutical Industries Ltd.、Teva Pharmaceutical Industries Ltd、West-Ward Pharmaceutical、Zydus Pharmaceuticals) ・結論 |
Idiopathic intracranial hypertension is characterized by a buildup of the cerebrospinal fluid causing increase in the blood volume in vessels surrounding the brain and increase in brain swelling. The increase in salt intake causes water retention in the body together with fat adding on to the calories thereby hindering the weight loss usually advised. Intracranial hypertension can also cause problem with body temperature control when there is overexposure to the sun and its heat.
Market Analysis and Insights: Global Idiopathic Intracranial Hypertension Treatment Market
The global Idiopathic Intracranial Hypertension Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Idiopathic Intracranial Hypertension Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Idiopathic Intracranial Hypertension Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Idiopathic Intracranial Hypertension Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Idiopathic Intracranial Hypertension Treatment market.
Global Idiopathic Intracranial Hypertension Treatment Scope and Market Size
Idiopathic Intracranial Hypertension Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Idiopathic Intracranial Hypertension Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Acetazolamide
Methazolamide
Furosemide
Topiramate
Others
Segment by Application
Hospital
Clinics
Ambulatory Surgery Centers
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Avkare, Inc
FDC
Heritage Pharmaceuticals Inc
Ingenus Pharmaceuticals
Janssen – Cilag Pharmaceuticals SA
Lannett Company,
Medtronic
MercuryPharma
Nostrum Laboratories Inc
Ingenus Pharmaceuticals
Janssen – Cilag Pharmaceuticals SA
SGPharma Pvt. Ltd.
Sophysa
Taro Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Idiopathic Intracranial Hypertension Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Acetazolamide
1.2.3 Methazolamide
1.2.4 Furosemide
1.2.5 Topiramate
1.2.6 Others
1.3 Market by Application
1.3.1 Global Idiopathic Intracranial Hypertension Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Ambulatory Surgery Centers
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Idiopathic Intracranial Hypertension Treatment Market Perspective (2016-2027)
2.2 Idiopathic Intracranial Hypertension Treatment Growth Trends by Regions
2.2.1 Idiopathic Intracranial Hypertension Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Idiopathic Intracranial Hypertension Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Idiopathic Intracranial Hypertension Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Idiopathic Intracranial Hypertension Treatment Industry Dynamic
2.3.1 Idiopathic Intracranial Hypertension Treatment Market Trends
2.3.2 Idiopathic Intracranial Hypertension Treatment Market Drivers
2.3.3 Idiopathic Intracranial Hypertension Treatment Market Challenges
2.3.4 Idiopathic Intracranial Hypertension Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Idiopathic Intracranial Hypertension Treatment Players by Revenue
3.1.1 Global Top Idiopathic Intracranial Hypertension Treatment Players by Revenue (2016-2021)
3.1.2 Global Idiopathic Intracranial Hypertension Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Idiopathic Intracranial Hypertension Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Idiopathic Intracranial Hypertension Treatment Revenue
3.4 Global Idiopathic Intracranial Hypertension Treatment Market Concentration Ratio
3.4.1 Global Idiopathic Intracranial Hypertension Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Idiopathic Intracranial Hypertension Treatment Revenue in 2020
3.5 Idiopathic Intracranial Hypertension Treatment Key Players Head office and Area Served
3.6 Key Players Idiopathic Intracranial Hypertension Treatment Product Solution and Service
3.7 Date of Enter into Idiopathic Intracranial Hypertension Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Idiopathic Intracranial Hypertension Treatment Breakdown Data by Type
4.1 Global Idiopathic Intracranial Hypertension Treatment Historic Market Size by Type (2016-2021)
4.2 Global Idiopathic Intracranial Hypertension Treatment Forecasted Market Size by Type (2022-2027)
5 Idiopathic Intracranial Hypertension Treatment Breakdown Data by Application
5.1 Global Idiopathic Intracranial Hypertension Treatment Historic Market Size by Application (2016-2021)
5.2 Global Idiopathic Intracranial Hypertension Treatment Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Idiopathic Intracranial Hypertension Treatment Market Size (2016-2027)
6.2 North America Idiopathic Intracranial Hypertension Treatment Market Size by Type
6.2.1 North America Idiopathic Intracranial Hypertension Treatment Market Size by Type (2016-2021)
6.2.2 North America Idiopathic Intracranial Hypertension Treatment Market Size by Type (2022-2027)
6.2.3 North America Idiopathic Intracranial Hypertension Treatment Market Size by Type (2016-2027)
6.3 North America Idiopathic Intracranial Hypertension Treatment Market Size by Application
6.3.1 North America Idiopathic Intracranial Hypertension Treatment Market Size by Application (2016-2021)
6.3.2 North America Idiopathic Intracranial Hypertension Treatment Market Size by Application (2022-2027)
6.3.3 North America Idiopathic Intracranial Hypertension Treatment Market Size by Application (2016-2027)
6.4 North America Idiopathic Intracranial Hypertension Treatment Market Size by Country
6.4.1 North America Idiopathic Intracranial Hypertension Treatment Market Size by Country (2016-2021)
6.4.2 North America Idiopathic Intracranial Hypertension Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Idiopathic Intracranial Hypertension Treatment Market Size (2016-2027)
7.2 Europe Idiopathic Intracranial Hypertension Treatment Market Size by Type
7.2.1 Europe Idiopathic Intracranial Hypertension Treatment Market Size by Type (2016-2021)
7.2.2 Europe Idiopathic Intracranial Hypertension Treatment Market Size by Type (2022-2027)
7.2.3 Europe Idiopathic Intracranial Hypertension Treatment Market Size by Type (2016-2027)
7.3 Europe Idiopathic Intracranial Hypertension Treatment Market Size by Application
7.3.1 Europe Idiopathic Intracranial Hypertension Treatment Market Size by Application (2016-2021)
7.3.2 Europe Idiopathic Intracranial Hypertension Treatment Market Size by Application (2022-2027)
7.3.3 Europe Idiopathic Intracranial Hypertension Treatment Market Size by Application (2016-2027)
7.4 Europe Idiopathic Intracranial Hypertension Treatment Market Size by Country
7.4.1 Europe Idiopathic Intracranial Hypertension Treatment Market Size by Country (2016-2021)
7.4.2 Europe Idiopathic Intracranial Hypertension Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Idiopathic Intracranial Hypertension Treatment Market Size (2016-2027)
8.2 Asia-Pacific Idiopathic Intracranial Hypertension Treatment Market Size by Type
8.2.1 Asia-Pacific Idiopathic Intracranial Hypertension Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Idiopathic Intracranial Hypertension Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Idiopathic Intracranial Hypertension Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Idiopathic Intracranial Hypertension Treatment Market Size by Application
8.3.1 Asia-Pacific Idiopathic Intracranial Hypertension Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Idiopathic Intracranial Hypertension Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Idiopathic Intracranial Hypertension Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Idiopathic Intracranial Hypertension Treatment Market Size by Region
8.4.1 Asia-Pacific Idiopathic Intracranial Hypertension Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Idiopathic Intracranial Hypertension Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Idiopathic Intracranial Hypertension Treatment Market Size (2016-2027)
9.2 Latin America Idiopathic Intracranial Hypertension Treatment Market Size by Type
9.2.1 Latin America Idiopathic Intracranial Hypertension Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Idiopathic Intracranial Hypertension Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Idiopathic Intracranial Hypertension Treatment Market Size by Type (2016-2027)
9.3 Latin America Idiopathic Intracranial Hypertension Treatment Market Size by Application
9.3.1 Latin America Idiopathic Intracranial Hypertension Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Idiopathic Intracranial Hypertension Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Idiopathic Intracranial Hypertension Treatment Market Size by Application (2016-2027)
9.4 Latin America Idiopathic Intracranial Hypertension Treatment Market Size by Country
9.4.1 Latin America Idiopathic Intracranial Hypertension Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Idiopathic Intracranial Hypertension Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Idiopathic Intracranial Hypertension Treatment Market Size (2016-2027)
10.2 Middle East & Africa Idiopathic Intracranial Hypertension Treatment Market Size by Type
10.2.1 Middle East & Africa Idiopathic Intracranial Hypertension Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Idiopathic Intracranial Hypertension Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Idiopathic Intracranial Hypertension Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Idiopathic Intracranial Hypertension Treatment Market Size by Application
10.3.1 Middle East & Africa Idiopathic Intracranial Hypertension Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Idiopathic Intracranial Hypertension Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Idiopathic Intracranial Hypertension Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Idiopathic Intracranial Hypertension Treatment Market Size by Country
10.4.1 Middle East & Africa Idiopathic Intracranial Hypertension Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Idiopathic Intracranial Hypertension Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Avkare, Inc
11.1.1 Avkare, Inc Company Details
11.1.2 Avkare, Inc Business Overview
11.1.3 Avkare, Inc Idiopathic Intracranial Hypertension Treatment Introduction
11.1.4 Avkare, Inc Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
11.1.5 Avkare, Inc Recent Development
11.2 FDC
11.2.1 FDC Company Details
11.2.2 FDC Business Overview
11.2.3 FDC Idiopathic Intracranial Hypertension Treatment Introduction
11.2.4 FDC Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
11.2.5 FDC Recent Development
11.3 Heritage Pharmaceuticals Inc
11.3.1 Heritage Pharmaceuticals Inc Company Details
11.3.2 Heritage Pharmaceuticals Inc Business Overview
11.3.3 Heritage Pharmaceuticals Inc Idiopathic Intracranial Hypertension Treatment Introduction
11.3.4 Heritage Pharmaceuticals Inc Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
11.3.5 Heritage Pharmaceuticals Inc Recent Development
11.4 Ingenus Pharmaceuticals
11.4.1 Ingenus Pharmaceuticals Company Details
11.4.2 Ingenus Pharmaceuticals Business Overview
11.4.3 Ingenus Pharmaceuticals Idiopathic Intracranial Hypertension Treatment Introduction
11.4.4 Ingenus Pharmaceuticals Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
11.4.5 Ingenus Pharmaceuticals Recent Development
11.5 Janssen – Cilag Pharmaceuticals SA
11.5.1 Janssen – Cilag Pharmaceuticals SA Company Details
11.5.2 Janssen – Cilag Pharmaceuticals SA Business Overview
11.5.3 Janssen – Cilag Pharmaceuticals SA Idiopathic Intracranial Hypertension Treatment Introduction
11.5.4 Janssen – Cilag Pharmaceuticals SA Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
11.5.5 Janssen – Cilag Pharmaceuticals SA Recent Development
11.6 Lannett Company,
11.6.1 Lannett Company, Company Details
11.6.2 Lannett Company, Business Overview
11.6.3 Lannett Company, Idiopathic Intracranial Hypertension Treatment Introduction
11.6.4 Lannett Company, Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
11.6.5 Lannett Company, Recent Development
11.7 Medtronic
11.7.1 Medtronic Company Details
11.7.2 Medtronic Business Overview
11.7.3 Medtronic Idiopathic Intracranial Hypertension Treatment Introduction
11.7.4 Medtronic Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
11.7.5 Medtronic Recent Development
11.8 MercuryPharma
11.8.1 MercuryPharma Company Details
11.8.2 MercuryPharma Business Overview
11.8.3 MercuryPharma Idiopathic Intracranial Hypertension Treatment Introduction
11.8.4 MercuryPharma Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
11.8.5 MercuryPharma Recent Development
11.9 Nostrum Laboratories Inc
11.9.1 Nostrum Laboratories Inc Company Details
11.9.2 Nostrum Laboratories Inc Business Overview
11.9.3 Nostrum Laboratories Inc Idiopathic Intracranial Hypertension Treatment Introduction
11.9.4 Nostrum Laboratories Inc Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
11.9.5 Nostrum Laboratories Inc Recent Development
11.10 Novast Holdings Ltd.
11.10.1 Novast Holdings Ltd. Company Details
11.10.2 Novast Holdings Ltd. Business Overview
11.10.3 Novast Holdings Ltd. Idiopathic Intracranial Hypertension Treatment Introduction
11.10.4 Novast Holdings Ltd. Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
11.10.5 Novast Holdings Ltd. Recent Development
11.11 Sanofi
11.11.1 Sanofi Company Details
11.11.2 Sanofi Business Overview
11.11.3 Sanofi Idiopathic Intracranial Hypertension Treatment Introduction
11.11.4 Sanofi Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
11.11.5 Sanofi Recent Development
11.12 SGPharma Pvt. Ltd.
11.12.1 SGPharma Pvt. Ltd. Company Details
11.12.2 SGPharma Pvt. Ltd. Business Overview
11.12.3 SGPharma Pvt. Ltd. Idiopathic Intracranial Hypertension Treatment Introduction
11.12.4 SGPharma Pvt. Ltd. Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
11.12.5 SGPharma Pvt. Ltd. Recent Development
11.13 Sophysa
11.13.1 Sophysa Company Details
11.13.2 Sophysa Business Overview
11.13.3 Sophysa Idiopathic Intracranial Hypertension Treatment Introduction
11.13.4 Sophysa Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
11.13.5 Sophysa Recent Development
11.14 Taro Pharmaceutical Industries Ltd.
11.14.1 Taro Pharmaceutical Industries Ltd. Company Details
11.14.2 Taro Pharmaceutical Industries Ltd. Business Overview
11.14.3 Taro Pharmaceutical Industries Ltd. Idiopathic Intracranial Hypertension Treatment Introduction
11.14.4 Taro Pharmaceutical Industries Ltd. Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
11.14.5 Taro Pharmaceutical Industries Ltd. Recent Development
11.15 Teva Pharmaceutical Industries Ltd
11.15.1 Teva Pharmaceutical Industries Ltd Company Details
11.15.2 Teva Pharmaceutical Industries Ltd Business Overview
11.15.3 Teva Pharmaceutical Industries Ltd Idiopathic Intracranial Hypertension Treatment Introduction
11.15.4 Teva Pharmaceutical Industries Ltd Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
11.15.5 Teva Pharmaceutical Industries Ltd Recent Development
11.16 West-Ward Pharmaceutical
11.16.1 West-Ward Pharmaceutical Company Details
11.16.2 West-Ward Pharmaceutical Business Overview
11.16.3 West-Ward Pharmaceutical Idiopathic Intracranial Hypertension Treatment Introduction
11.16.4 West-Ward Pharmaceutical Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
11.16.5 West-Ward Pharmaceutical Recent Development
11.17 Zydus Pharmaceuticals
11.17.1 Zydus Pharmaceuticals Company Details
11.17.2 Zydus Pharmaceuticals Business Overview
11.17.3 Zydus Pharmaceuticals Idiopathic Intracranial Hypertension Treatment Introduction
11.17.4 Zydus Pharmaceuticals Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
11.17.5 Zydus Pharmaceuticals Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Idiopathic Intracranial Hypertension Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Acetazolamide
Table 3. Key Players of Methazolamide
Table 4. Key Players of Furosemide
Table 5. Key Players of Topiramate
Table 6. Key Players of Others
Table 7. Global Idiopathic Intracranial Hypertension Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Idiopathic Intracranial Hypertension Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Idiopathic Intracranial Hypertension Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Idiopathic Intracranial Hypertension Treatment Market Share by Regions (2016-2021)
Table 11. Global Idiopathic Intracranial Hypertension Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Idiopathic Intracranial Hypertension Treatment Market Share by Regions (2022-2027)
Table 13. Idiopathic Intracranial Hypertension Treatment Market Trends
Table 14. Idiopathic Intracranial Hypertension Treatment Market Drivers
Table 15. Idiopathic Intracranial Hypertension Treatment Market Challenges
Table 16. Idiopathic Intracranial Hypertension Treatment Market Restraints
Table 17. Global Idiopathic Intracranial Hypertension Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Idiopathic Intracranial Hypertension Treatment Market Share by Players (2016-2021)
Table 19. Global Top Idiopathic Intracranial Hypertension Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Idiopathic Intracranial Hypertension Treatment as of 2020)
Table 20. Ranking of Global Top Idiopathic Intracranial Hypertension Treatment Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Idiopathic Intracranial Hypertension Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Idiopathic Intracranial Hypertension Treatment Product Solution and Service
Table 24. Date of Enter into Idiopathic Intracranial Hypertension Treatment Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Idiopathic Intracranial Hypertension Treatment Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Idiopathic Intracranial Hypertension Treatment Revenue Market Share by Type (2016-2021)
Table 28. Global Idiopathic Intracranial Hypertension Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Idiopathic Intracranial Hypertension Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Idiopathic Intracranial Hypertension Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Idiopathic Intracranial Hypertension Treatment Revenue Market Share by Application (2016-2021)
Table 32. Global Idiopathic Intracranial Hypertension Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Idiopathic Intracranial Hypertension Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Idiopathic Intracranial Hypertension Treatment Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Idiopathic Intracranial Hypertension Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Idiopathic Intracranial Hypertension Treatment Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Idiopathic Intracranial Hypertension Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Idiopathic Intracranial Hypertension Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Idiopathic Intracranial Hypertension Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Idiopathic Intracranial Hypertension Treatment Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Idiopathic Intracranial Hypertension Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Idiopathic Intracranial Hypertension Treatment Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Idiopathic Intracranial Hypertension Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Idiopathic Intracranial Hypertension Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Idiopathic Intracranial Hypertension Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Idiopathic Intracranial Hypertension Treatment Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Idiopathic Intracranial Hypertension Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Idiopathic Intracranial Hypertension Treatment Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Idiopathic Intracranial Hypertension Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Idiopathic Intracranial Hypertension Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Idiopathic Intracranial Hypertension Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Idiopathic Intracranial Hypertension Treatment Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Idiopathic Intracranial Hypertension Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Idiopathic Intracranial Hypertension Treatment Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Idiopathic Intracranial Hypertension Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Idiopathic Intracranial Hypertension Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Idiopathic Intracranial Hypertension Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Idiopathic Intracranial Hypertension Treatment Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Idiopathic Intracranial Hypertension Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Idiopathic Intracranial Hypertension Treatment Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Idiopathic Intracranial Hypertension Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Idiopathic Intracranial Hypertension Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Idiopathic Intracranial Hypertension Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 64. Avkare, Inc Company Details
Table 65. Avkare, Inc Business Overview
Table 66. Avkare, Inc Idiopathic Intracranial Hypertension Treatment Product
Table 67. Avkare, Inc Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021) & (US$ Million)
Table 68. Avkare, Inc Recent Development
Table 69. FDC Company Details
Table 70. FDC Business Overview
Table 71. FDC Idiopathic Intracranial Hypertension Treatment Product
Table 72. FDC Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021) & (US$ Million)
Table 73. FDC Recent Development
Table 74. Heritage Pharmaceuticals Inc Company Details
Table 75. Heritage Pharmaceuticals Inc Business Overview
Table 76. Heritage Pharmaceuticals Inc Idiopathic Intracranial Hypertension Treatment Product
Table 77. Heritage Pharmaceuticals Inc Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021) & (US$ Million)
Table 78. Heritage Pharmaceuticals Inc Recent Development
Table 79. Ingenus Pharmaceuticals Company Details
Table 80. Ingenus Pharmaceuticals Business Overview
Table 81. Ingenus Pharmaceuticals Idiopathic Intracranial Hypertension Treatment Product
Table 82. Ingenus Pharmaceuticals Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021) & (US$ Million)
Table 83. Ingenus Pharmaceuticals Recent Development
Table 84. Janssen - Cilag Pharmaceuticals SA Company Details
Table 85. Janssen - Cilag Pharmaceuticals SA Business Overview
Table 86. Janssen - Cilag Pharmaceuticals SA Idiopathic Intracranial Hypertension Treatment Product
Table 87. Janssen - Cilag Pharmaceuticals SA Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021) & (US$ Million)
Table 88. Janssen - Cilag Pharmaceuticals SA Recent Development
Table 89. Lannett Company, Company Details
Table 90. Lannett Company, Business Overview
Table 91. Lannett Company, Idiopathic Intracranial Hypertension Treatment Product
Table 92. Lannett Company, Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021) & (US$ Million)
Table 93. Lannett Company, Recent Development
Table 94. Medtronic Company Details
Table 95. Medtronic Business Overview
Table 96. Medtronic Idiopathic Intracranial Hypertension Treatment Product
Table 97. Medtronic Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021) & (US$ Million)
Table 98. Medtronic Recent Development
Table 99. MercuryPharma Company Details
Table 100. MercuryPharma Business Overview
Table 101. MercuryPharma Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021) & (US$ Million)
Table 102. MercuryPharma Recent Development
Table 103. Nostrum Laboratories Inc Company Details
Table 104. Nostrum Laboratories Inc Business Overview
Table 105. Nostrum Laboratories Inc Idiopathic Intracranial Hypertension Treatment Product
Table 106. Nostrum Laboratories Inc Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021) & (US$ Million)
Table 107. Nostrum Laboratories Inc Recent Development
Table 108. Novast Holdings Ltd. Company Details
Table 109. Novast Holdings Ltd. Business Overview
Table 110. Novast Holdings Ltd. Idiopathic Intracranial Hypertension Treatment Product
Table 111. Novast Holdings Ltd. Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021) & (US$ Million)
Table 112. Novast Holdings Ltd. Recent Development
Table 113. Sanofi Company Details
Table 114. Sanofi Business Overview
Table 115. Sanofi Idiopathic Intracranial Hypertension Treatment Product
Table 116. Sanofi Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021) & (US$ Million)
Table 117. Sanofi Recent Development
Table 118. SGPharma Pvt. Ltd. Company Details
Table 119. SGPharma Pvt. Ltd. Business Overview
Table 120. SGPharma Pvt. Ltd. Idiopathic Intracranial Hypertension Treatment Product
Table 121. SGPharma Pvt. Ltd. Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021) & (US$ Million)
Table 122. SGPharma Pvt. Ltd. Recent Development
Table 123. Sophysa Company Details
Table 124. Sophysa Business Overview
Table 125. Sophysa Idiopathic Intracranial Hypertension Treatment Product
Table 126. Sophysa Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021) & (US$ Million)
Table 127. Sophysa Recent Development
Table 128. Taro Pharmaceutical Industries Ltd. Company Details
Table 129. Taro Pharmaceutical Industries Ltd. Business Overview
Table 130. Taro Pharmaceutical Industries Ltd. Idiopathic Intracranial Hypertension Treatment Product
Table 131. Taro Pharmaceutical Industries Ltd. Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021) & (US$ Million)
Table 132. Taro Pharmaceutical Industries Ltd. Recent Development
Table 133. Teva Pharmaceutical Industries Ltd Company Details
Table 134. Teva Pharmaceutical Industries Ltd Business Overview
Table 135. Teva Pharmaceutical Industries Ltd Idiopathic Intracranial Hypertension Treatment Product
Table 136. Teva Pharmaceutical Industries Ltd Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021) & (US$ Million)
Table 137. Teva Pharmaceutical Industries Ltd Recent Development
Table 138. West-Ward Pharmaceutical Company Details
Table 139. West-Ward Pharmaceutical Business Overview
Table 140. West-Ward Pharmaceutical Idiopathic Intracranial Hypertension Treatment Product
Table 141. West-Ward Pharmaceutical Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021) & (US$ Million)
Table 142. West-Ward Pharmaceutical Recent Development
Table 143. Zydus Pharmaceuticals Company Details
Table 144. Zydus Pharmaceuticals Business Overview
Table 145. Zydus Pharmaceuticals Idiopathic Intracranial Hypertension Treatment Product
Table 146. Zydus Pharmaceuticals Revenue in Idiopathic Intracranial Hypertension Treatment Business (2016-2021) & (US$ Million)
Table 147. Zydus Pharmaceuticals Recent Development
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Idiopathic Intracranial Hypertension Treatment Market Share by Type: 2020 VS 2027
Figure 2. Acetazolamide Features
Figure 3. Methazolamide Features
Figure 4. Furosemide Features
Figure 5. Topiramate Features
Figure 6. Others Features
Figure 7. Global Idiopathic Intracranial Hypertension Treatment Market Share by Application: 2020 VS 2027
Figure 8. Hospital Case Studies
Figure 9. Clinics Case Studies
Figure 10. Ambulatory Surgery Centers Case Studies
Figure 11. Idiopathic Intracranial Hypertension Treatment Report Years Considered
Figure 12. Global Idiopathic Intracranial Hypertension Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Idiopathic Intracranial Hypertension Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Idiopathic Intracranial Hypertension Treatment Market Share by Regions: 2020 VS 2027
Figure 15. Global Idiopathic Intracranial Hypertension Treatment Market Share by Regions (2022-2027)
Figure 16. Global Idiopathic Intracranial Hypertension Treatment Market Share by Players in 2020
Figure 17. Global Top Idiopathic Intracranial Hypertension Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Idiopathic Intracranial Hypertension Treatment as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Idiopathic Intracranial Hypertension Treatment Revenue in 2020
Figure 19. Global Idiopathic Intracranial Hypertension Treatment Revenue Market Share by Type (2016-2021)
Figure 20. Global Idiopathic Intracranial Hypertension Treatment Revenue Market Share by Type (2022-2027)
Figure 21. North America Idiopathic Intracranial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Idiopathic Intracranial Hypertension Treatment Market Share by Type (2016-2027)
Figure 23. North America Idiopathic Intracranial Hypertension Treatment Market Share by Application (2016-2027)
Figure 24. North America Idiopathic Intracranial Hypertension Treatment Market Share by Country (2016-2027)
Figure 25. United States Idiopathic Intracranial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Idiopathic Intracranial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Idiopathic Intracranial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Idiopathic Intracranial Hypertension Treatment Market Share by Type (2016-2027)
Figure 29. Europe Idiopathic Intracranial Hypertension Treatment Market Share by Application (2016-2027)
Figure 30. Europe Idiopathic Intracranial Hypertension Treatment Market Share by Country (2016-2027)
Figure 31. Germany Idiopathic Intracranial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Idiopathic Intracranial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Idiopathic Intracranial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Idiopathic Intracranial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Idiopathic Intracranial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Idiopathic Intracranial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Idiopathic Intracranial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Idiopathic Intracranial Hypertension Treatment Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Idiopathic Intracranial Hypertension Treatment Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Idiopathic Intracranial Hypertension Treatment Market Share by Region (2016-2027)
Figure 41. China Idiopathic Intracranial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Idiopathic Intracranial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Idiopathic Intracranial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Idiopathic Intracranial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Idiopathic Intracranial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Idiopathic Intracranial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Idiopathic Intracranial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Idiopathic Intracranial Hypertension Treatment Market Share by Type (2016-2027)
Figure 49. Latin America Idiopathic Intracranial Hypertension Treatment Market Share by Application (2016-2027)
Figure 50. Latin America Idiopathic Intracranial Hypertension Treatment Market Share by Country (2016-2027)
Figure 51. Mexico Idiopathic Intracranial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Idiopathic Intracranial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Idiopathic Intracranial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Idiopathic Intracranial Hypertension Treatment Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Idiopathic Intracranial Hypertension Treatment Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Idiopathic Intracranial Hypertension Treatment Market Share by Country (2016-2027)
Figure 57. Turkey Idiopathic Intracranial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Idiopathic Intracranial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Idiopathic Intracranial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Avkare, Inc Revenue Growth Rate in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
Figure 61. FDC Revenue Growth Rate in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
Figure 62. Heritage Pharmaceuticals Inc Revenue Growth Rate in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
Figure 63. Ingenus Pharmaceuticals Revenue Growth Rate in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
Figure 64. Janssen - Cilag Pharmaceuticals SA Revenue Growth Rate in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
Figure 65. Lannett Company, Revenue Growth Rate in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
Figure 66. Medtronic Revenue Growth Rate in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
Figure 67. MercuryPharma Revenue Growth Rate in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
Figure 68. Nostrum Laboratories Inc Revenue Growth Rate in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
Figure 69. Novast Holdings Ltd. Revenue Growth Rate in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
Figure 70. Sanofi Revenue Growth Rate in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
Figure 71. SGPharma Pvt. Ltd. Revenue Growth Rate in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
Figure 72. Sophysa Revenue Growth Rate in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
Figure 73. Taro Pharmaceutical Industries Ltd. Revenue Growth Rate in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
Figure 74. Teva Pharmaceutical Industries Ltd Revenue Growth Rate in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
Figure 75. West-Ward Pharmaceutical Revenue Growth Rate in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
Figure 76. Zydus Pharmaceuticals Revenue Growth Rate in Idiopathic Intracranial Hypertension Treatment Business (2016-2021)
Figure 77. Bottom-up and Top-down Approaches for This Report
Figure 78. Data Triangulation
Figure 79. Key Executives Interviewed